Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Sep-Oct;23(5):195-202.
doi: 10.1097/DER.0b013e31826e43ed.

T-cell inhibitors: a bench-to-bedside review

Shinjita Das  1 , Kiyoshi Ariizumi, Ponciano D Cruz Jr
Affiliations
Review

T-cell inhibitors: a bench-to-bedside review

Shinjita Das et al. Dermatitis. 2012 Sep-Oct.

Abstract

Allergic contact dermatitis is the quintessential example of a delayed-in-time and T-cell-mediated immune response. In the last decade, many of the molecular events required to initiate (or block) such a response have been uncovered. Textbook and journal reviews have emphasized the costimulatory requirements, with less focus on the coinhibitory signals that are of equal importance in understanding this central event of adaptive immunity. To fill this gap, we offer a compendium of discoveries characterizing the ligand-receptor pairs inhibiting T-cell activation and of selected illnesses and therapeutic applications that illuminate their role in health and disease.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: For the remaining author none were declared.

Figures

Figure 1
Figure 1
apc regulation of T-cell activation
See this image and copyright information in PMC

References

    1. Curtsinger JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol. 2010;22:333–340. - PMC - PubMed
    1. Smith-Garvin JE, Koretzky GA, Jordan MS. T cell activation. Annu Rev Immunol. 2009;27:591–619. - PMC - PubMed
    1. Carreno BM, Collins M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu Rev Immunol. 2002;20:29–53. - PubMed
    1. Murphy KM, Nelson CA, Sedy JR. Balancing co-stimulation and inhibition with BTLA and HVEM. Nat Rev Immunol. 2006;6:671–681. - PubMed
    1. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007;19:813–824. - PubMed

Publication types

MeSH terms

Substances